Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

被引：3
作者：
Zhao, Shuang [1 ]
Liu, Yanyan [1 ]
Yao, Zhihua [2 ]
Yan, Zheng [3 ]
Yao, Shuna [1 ]
Chu, Junfeng [1 ]
Wang, Haiying [1 ]
Zhang, Jiuyang [1 ]
Zhang, Peipei [1 ]
Zhou, Wenping [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-166829
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6579 / 6580
页数：2
相关论文
共 50 条
  • [41] A phase II clinical trial of ZD1839 ( gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Dennison, S. K.
    Jacobs, S. A.
    Wilson, J.
    Seeger, J.
    Cescon, T.
    Raymond, J. M.
    Geyer, C. E.
    Wolmark, N.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K. Dennison
    Samuel A. Jacobs
    John W. Wilson
    Janell Seeger
    Terrence P. Cescon
    Jane M. Raymond
    Charles E. Geyer
    Norman Wolmark
    Sandra M. Swain
    Investigational New Drugs, 2007, 25 : 545 - 551
  • [43] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
  • [44] Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study
    Ansell, Stephen Maxted
    Younes, Anas
    Connors, Joseph M.
    Gallamini, Andrea
    Kim, Won Seog
    Friedberg, Jonathan W.
    Feldman, Tatyana A.
    Collins, Graham
    Bartlett, Nancy
    Wang, Jingyuan
    Brady, Kelly
    Sachs, Jessica
    Huebner, Dirk
    Hunder, Naomi N. H.
    Radford, John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [46] Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: A minnie pearl cancer research network phase II trial
    Hainsworth, John D.
    Yardley, Denise A.
    Spigel, David R.
    Meluch, Anthony A.
    Rinaldi, David
    Schnell, Frederick M.
    Greco, F. Anthony
    CANCER INVESTIGATION, 2006, 24 (05) : 469 - 473
  • [47] First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial
    Hainsworth, JD
    Litchy, S
    Lamb, MR
    Rodriguez, GI
    Scroggin, C
    Greco, FA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 36 - 42
  • [48] Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial
    Mateos, Antonio Vega
    Alfaro, Hector Alejandro Vaquera
    Vasquez, Ana Cristina Tejada
    Lopez-Garcia, Yadith Karina
    Garcia-Salas, Gerardo
    Cantu, Olga
    Gomez-De Leon, Andres
    Gomez-Almaguer, David
    Tarin-Arzaga, Luz
    Gutierrez-Aguirre, Cesar Homero
    Colunga-Pedraza, Perla R.
    BLOOD, 2024, 144 : 1665 - 1666
  • [49] Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
    Ren, Shengxiang
    Chen, Jianhua
    Xu, Xingxiang
    Jiang, Tao
    Cheng, Ying
    Chen, Gongyan
    Pan, Yueyin
    Fang, Yong
    Wang, Qiming
    Huang, Yunchao
    Yao, Wenxiu
    Wang, Rui
    Li, Xingya
    Zhang, Wei
    Zhang, Yanjun
    Hu, Sheng
    Guo, Renhua
    Shi, Jianhua
    Wang, Zhiwu
    Cao, Peiguo
    Wang, Donglin
    Fang, Jian
    Luo, Hui
    Geng, Yi
    Xing, Chunyan
    Lv, Dongqing
    Zhang, Yiping
    Yu, Junyan
    Cang, Shundong
    Yang, Zeyu
    Shi, Wei
    Zou, Jianjun
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 544 - 557
  • [50] Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
    Neri, B.
    Pantaleo, P.
    Giommoni, E.
    Grifoni, R.
    Paoletti, C.
    Rotella, V.
    Pantalone, D.
    Taddei, A.
    Mercatelli, A.
    Tonelli, P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (07) : 1043 - 1046
12345